AI-powered biotechnology company BenevolentAI, in collaboration with AstraZeneca, has announced that a novel target for systemic lupus erythematosus (SLE) has been added to its discovery portfolio.
The partnership, initiated in 2019, leverages BenevolentAI's AI drug discovery platform to develop novel therapeutic targets tested and validated by AstraZeneca. The collaborative research was initiated focusing on idiopathic pulmonary fibrosis and chronic kidney disease and was extended in 2022 , expanding the study to include heart failure and SLE.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.